Vicks Childrens Liquid
NDC Package 69423-982-06
Package Information
Vicks Childrens (phenylephrine hcl, dextromethorphan hbr, guaifenesin) liquids is take only as directeduse dose cup provideddo not exceed 4 doses per 24 hrs adults & children 12 yrs & over 30 mL every 4 hrs children 6 to under 12 yrs 15 mL every 4 hrs children 4 to under 6 yrs do not use unless directed by a doctor children under 4 yrs do not use take only as directeduse dose cup provideddo not exceed 4 doses per 24 hrsadults & children 12 yrs & over 30 mL every 4 hrs children 6 to under 12 yrs 15 mL every 4 hrs children 4 to under 6 yrs ask a doctor children under 4 yrs do not use. This formulation utilizes a liquid delivery system. Marketed by The Procter & Gamble Manufacturing Company, this product is identified by NDC 69423-982 and is authorized under FDA application M012.
Identification & Billing
- RxCUI: 2166123 - dextromethorphan Hbr 10 MG / guaiFENesin 200 MG / phenylephrine HCl 5 MG in 15 mL Oral Solution
- RxCUI: 2166123 - dextromethorphan hydrobromide 0.667 MG/ML / guaifenesin 13.3 MG/ML / phenylephrine hydrochloride 0.333 MG/ML Oral Solution
- RxCUI: 2166123 - dextromethorphan hydrobromide 10 MG / guaifenesin 200 MG / phenylephrine hydrochloride 5 MG per 15 ML Oral Solution
- RxCUI: 2166129 - diphenhydrAMINE HCl 12.5 MG / phenylephrine HCl 5 MG in 15 mL Oral Solution
- RxCUI: 2166129 - diphenhydramine hydrochloride 0.833 MG/ML / phenylephrine hydrochloride 0.333 MG/ML Oral Solution
Clinical Specifications
- Adrenergic alpha1-Agonists - [MoA] (Mechanism of Action)
- Decreased Respiratory Secretion Viscosity - [PE] (Physiologic Effect)
- Expectorant - [EPC] (Established Pharmacologic Class)
- Increased Respiratory Secretions - [PE] (Physiologic Effect)
- Sigma-1 Agonist - [EPC] (Established Pharmacologic Class)
- Sigma-1 Receptor Agonists - [MoA] (Mechanism of Action)
- Uncompetitive N-methyl-D-aspartate Receptor Antagonist - [EPC] (Established Pharmacologic Class)
- Uncompetitive NMDA Receptor Antagonists - [MoA] (Mechanism of Action)
- alpha-1 Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 69423 - The Procter & Gamble Manufacturing Company
- 69423-982 - Vicks Childrens
- 69423-982-06 - 177 mL in 1 BOTTLE, PLASTIC
- 69423-982 - Vicks Childrens
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69423-982-06 identifies a specific commercial package of 177 ml in 1 bottle, plastic of Vicks Childrens Cough Congestion, a human over the counter drug labeled by The Procter & Gamble Manufacturing Company. This liquid is formulated for oral use and contains dextromethorphan hydrobromide; guaifenesin; phenylephrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by The Procter & Gamble Manufacturing Company on April 22, 2019. The current certification is valid through December 31, 2026.
How is this The Procter & Gamble Manufacturing Company product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69423098206. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.